Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 3Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Noonan Syndrome 5 1

Interventions

Specimen Handling 191Magnetic Resonance Spectroscopy 141Biopsy 102pembrolizumab 82Carboplatin 76Cisplatin 68Nivolumab 62Radiotherapy 51Paclitaxel 51Gemcitabine 50Cyclophosphamide 48Dexamethasone 46durvalumab 39Radiation 39atezolizumab 36Pemetrexed 36olaparib 34Rituximab 34venetoclax 33Etoposide 33Doxorubicin 32Lenalidomide 31X-Rays 30Prednisone 30Bevacizumab 30Docetaxel 28Disulfides 28Immunoglobulin G 27Vincristine 26Ipilimumab 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Antineoplastic Agents × 30 days × Clear all
NCT05566795 2026-05-14

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

Day One Biopharmaceuticals, Inc.

Phase 3 Active not recruiting
418 enrolled

Noonan Syndrome 5

Data powered by HemOnc (CC BY 4.0) Colophon âš¡